Related Experiment Video
Updated: Apr 24, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan-Tumor
Zhe Wang1, Lin Chen2, Wei Rao3
1Department of Pathology, Xijing Hospital and School of Basic Medicine Fourth Military Medical University Xi'an China.
Abstract:
Human epidermal growth factor receptor 2 (HER2) is a key biomarker and therapeutic target in several malignancies, including breast, gastric, and other solid tumors. Recent advancements in cancer molecular profiling and the Food and Drug Administration's approval of trastuzumab deruxtecan for HER2-positive pan-tumor indications have highlighted the broader relevance of HER2 alterations across diverse cancers. However, the lack of standardized guidelines for HER2 testing in a pan-tumor context creates variability in clinical practice, hindering the optimal implementation of HER2-targeted therapies beyond traditional indications. To address this gap, a multidisciplinary panel of Chinese experts has developed a consensus providing comprehensive recommendations on diagnostic strategies, testing methodologies, and clinical applications of HER2 overexpression detection. By establishing a unified framework for HER2 overexpression assessment, this consensus aims to enhance the precision of HER2 testing, optimize patient selection for targeted therapies, and improve clinical outcomes across a wide spectrum of HER2 overexpression malignancies.
Insights
Chinese experts developed consensus recommendations for Human Epidermal Growth Factor Receptor 2 (HER2) testing. This aims to standardize HER2 assessment, optimize targeted therapy selection, and improve outcomes in HER2-positive cancers.
Area of Science:
- Oncology
- Molecular Diagnostics
- Cancer Therapeutics
Background:
- Human Epidermal Growth Factor Receptor 2 (HER2) is a critical biomarker and therapeutic target in various cancers, including breast and gastric tumors.
- Recent approvals of HER2-targeted therapies for pan-tumor indications underscore the expanding clinical relevance of HER2 alterations.
- Current lack of standardized HER2 testing guidelines in a pan-tumor context leads to clinical practice variability and suboptimal therapy implementation.
Purpose of the Study:
- To address the need for standardized HER2 testing across diverse malignancies.
- To provide comprehensive recommendations for diagnostic strategies and testing methodologies for HER2 overexpression.
- To optimize the clinical application of HER2-targeted therapies beyond traditional indications.
Main Methods:
- Development of a consensus by a multidisciplinary panel of Chinese experts.
- Review of current diagnostic strategies and testing methodologies for HER2 overexpression.
- Formulation of recommendations for clinical application of HER2 detection.
Main Results:
- Establishment of a unified framework for assessing HER2 overexpression.
- Recommendations cover diagnostic strategies, testing methodologies, and clinical applications.
- The consensus provides guidance for consistent and precise HER2 testing.
Conclusions:
- The developed consensus aims to enhance the precision of HER2 testing.
- Optimizing patient selection for HER2-targeted therapies is a key outcome.
- Improved clinical outcomes are anticipated across a spectrum of HER2 overexpression malignancies.
More Related Videos
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
